NCT04471987招募中1 期
A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19.
Philogen S.p.A.12 个研究点 分布在 3 个国家目标入组 80 人开始时间: 2020年7月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 80
- 试验地点
- 12
- 主要终点
- For Part I: DLT
研究概览
简要总结
The purpose of this study is to describe the safety, tolerability and early signs of efficacy of the antibody-cytokine fusion protein IL12-L19L19 in patients with advanced or metastatic solid carcinomas, after previous immune checkpoint blockade therapy.
The primary objective of the study is to evaluate the safety of IL12-L19L19 and to establish MTD in order to establish a recommended dose (RD).
The secondary objectives of the study are to assess early signs of efficacy, the determination of pharmacokinetic (PK) properties and the immunogenicity of IL12-L19L19.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female aged 18 to 80 years at the time of consent.
- •Patients must have a histological or cytological diagnosis of advanced/metastatic immunotherapy responsive solid carcinoma for which immune checkpoint blockade is approved, that has progressed on immune checkpoint-blockade therapy.
- •Patients must have received an immune checkpoint blockade therapy-based regimen as prior treatment.
- •Only patients without other therapeutic alternatives with curative or survival prolonging potential per investigator judgement are able to participate.
- •Subjects must have had clinical benefit in terms of disease control (CR/PR/SD) while on checkpoint inhibitor treatment defined as ≥ 3 month free from progression from initial imaging documenting advanced/metastatic disease followed by radiographic disease progression after checkpoint inhibitor per investigator's opinion.
- •Patients must have progressive disease or relapse at the time of screening.
- •Patients may have previously received chemotherapy, immunotherapy or radiation therapy. Such therapies must be completed at least 4 weeks prior to study drug administration. Radiotherapy within 4 weeks of the first dose of study drug, is allowed for palliative radiotherapy to a limited field, such as for the treatment of bone pain or a focally painful tumor mass. During the expansion part, to allow evaluation of response to treatment, patients must have remaining measurable disease that has not been irradiated.
- •Eastern cooperative oncology group (ECOG) performance status ≤
- •Patient has an estimated life expectancy of at least 12 weeks.
- •At least one unidimensionally measurable lesion either by computed tomography (CT), MRI or PET/CT as defined by RECIST (v. 1.1) for solid tumors.
- •Documented negative test for HIV-HBV-HCV. For HBV serology: the determination of HBsAg, and anti-HBcAg-Ab is required. In patients with serology documenting previous exposure to HBV (i.e., anti-HBs Ab with no history of vaccination and/or anti-HBc Ab), negative serum HBV-DNA is required. For HCV: HCV-RNA or HCV antibody test. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
- •All acute toxic effects (excluding alopecia and fatigue) of any prior therapy (including surgery, radiation therapy, chemotherapy) must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) (v. 5.0) Grade ≤
- •Full resolution of checkpoint blockade therapy-related adverse effects (including immune-related adverse effects) and no treatment for these AEs for at least 4 weeks prior to the time of enrollment. The only exception are patients with checkpoint blockade induced hypothyroidism and hypophysitis if these patients are on stable maintenance therapy with on levothyroxine or steroids (≤ 10 mg prednisone equivalent) for at least 2 months prior dosing.
- •No history of severe immune related adverse effects from prior given immune checkpoint blockade therapy (CTCAE Grade 4; CTCAE Grade 3 requiring treatment >4 weeks).
- •Female patients: negative blood pregnancy test at Screening for women of childbearing potential (WOCBP)*. WOCBP must agree to use, from the screening to six months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group (www.hma.eu/ctfg.html) and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion or vasectomized partner.
- •Male patients: male subjects able to father children must agree to use two acceptable methods of contraception throughout the study (e.g. condom with spermicidal gel). Double-barrier contraception is required.
- •Negative TB test (e.g. Mantoux or Quantiferon assay).
- •A personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study and has given consent to participate in the study.
- •Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
- •Women of childbearing potential are defined as females who have experienced menarche, are not postmenopausal (12 months with no menses without an alternative medical cause) and are not permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral oophorectomy or bilateral salpingectomy)
排除标准
- •Subjects who participated in an investigational drug or device study within 4 weeks prior to study treatment start.
- •Radiotherapy within 4 weeks prior to study treatment start.
- •Active or history of autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
- •Patients with primary brain tumors or CNS disease (including brain metastases).
- •Patient taking herbal medications within 7 days prior to study treatment start.
- •Known history of allergy to an excipient in study medication or any other intravenously administered human proteins/peptides/antibodies.
- •Absolute neutrophil count (ANC) < 1.5 x 10^9/L, platelets < 100 x 10^9/L or haemoglobin (Hb) < 9.0 g/dl.
- •Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min or serum creatinine > 1.5 ULN.
- •Inadequate liver function (ALT, AST, ALP ≥ 2.5 x ULN or total bilirubin ≥ 2.0 x ULN). At the discretion of the investigator, an increased exclusion threshold for patients with liver metastasis can be accepted as follows: ALT, AST, ALP and bilirubin ≥ 5 x ULN.
- •Any severe concomitant condition which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol, in the opinion of the investigator.
- •History within the last year of cerebrovascular disease and/or acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris.
- •Heart insufficiency (> Grade II, New York Heart Association (NYHA) criteria).
- •Clinically significant cardiac arrhythmias or requiring permanent medication.
- •Abnormal LVEF or any other abnormalities observed during baseline ECG and echocardiogram investigations that are considered as clinically significant by the investigator. Subjects with current, or a history of QT/QTc prolongation would be excluded. In particular:
- •patients with a marked prolongation of QT/QTc interval (e.g., repeated demonstration of QTc >480 milliseconds using Fredricia's QT correction formula) are excluded;
- •patients with a history of risk factors for Torsades de Pointes (e.g., heart failure, hypokalemia, family history of prolonged QT syndrome) are excluded;
- •patients who require the use of concomitant medications that prolong the QT/QTc interval are excluded.
- •Uncontrolled hypertension as defined by systolic blood pressure ≥ 140 mmHg and diastolic blood pressure ≥ 90 mmHg at 3 consecutive measurements performed within one week. Note: if the first blood pressure measurement is below threshold for systolic or diastolic blood pressure, it is not required to repeat the measurement.
- •Ischemic peripheral vascular disease (Grade IIb-IV according to Leriche-Fontaine classification).
- •Severe diabetic retinopathy such as severe non-proliferative retinopathy and proliferative retinopathy.
- •Major trauma including major surgery (such as abdominal/cardiac/thoracic surgery) within 4 weeks of study treatment start.
- •Pregnancy or breast-feeding.
- •Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any other immunosuppressive therapy within 14 days prior to study treatment start. Topical, inhaled, nasal and ophthalmic steroids are allowed.
- •Presence of active and uncontrolled infections or other severe concurrent disease, which, in the opinion of the investigator, would place the patient at undue risk or interfere with the study.
- •Concurrent or previous malignancies (other than the indication for this trial), unless a complete remission without further recurrence was achieved at least 2 years prior to study treatment start.
- •Growth factors or immunomodulatory agents within 7 days prior to study treatment start.
- •Serious, non-healing wound, ulcer or bone fracture.
- •Deep vein thrombosis, pulmonary embolism or other acute vascular events within 6 months.
- •Requirement of concurrent use of other anti-cancer treatments or agents other than study medication.
- •Any recent live vaccination within 4 weeks prior to treatment or plan to receive vaccination during the study.
研究组 & 干预措施
Treatment
Experimental
The study will take place in two stages:
- In the dose escalation part, participants will be enrolled in cohorts and will be treated with different doses of IL12-L19L19 in order to identify a RD to be further explored in the subsequent dose expansion part. In the dose escalation part, patients will be treated in cohorts of 1 to 6 patients with escalating doses of IL12-L19L19 until the MAD is reached.
- Following successful identification of the RD, the study will proceed with a dose expansion part and 20 patients will be treated at the RD dose level.
干预措施: IL12-L19L19 (Drug)
结局指标
主要结局
For Part I: DLT
时间窗: From Day 1 to Day 28 of the treatment
Occurrence of dose limiting toxicity (DLT) in dose escalation part of the study.
Safety (DILI)
时间窗: Throughout study completion for each patient, a maximum of 24 weeks for each patient
Evaluation of possible Drug Induce Liver Injury, caused by IL12-L19L19, assessed by Common Toxicity Criteria (version 5.0, CTCAE)
For Part I: MAD
时间窗: From Day 1 to Day 28 of the treatment
Definition of Maximum Administered Dose (MAD) (in dose escalation part). The MAD is defined when at least two patients within a cohort of 2-6 patients experience a DLT (i.e., ≥33% of patients with a DLT at that dose level)
For Part I: MTD and RD
时间窗: From Day 1 to Day 28 of the treatment
Defining the Maximum Tolerated Dose (MTD) and recommendation of the Recommended Dose (RD): when the DLT rate reaches 33% in a cohort, the next lower dose level will be called the MTD (so long as the DLT rate is less than 33%). Accordingly, the recommended dose (RD) for the Dose Expansion cohort will be the MTD.
Safety (AE)
时间窗: Throughout study completion for each patient
Safety of administration of IL12-L19L19, through an assessed by Common Toxicity Criteria (version 5.0, CTCAE)
Safety (SAE)
时间窗: Throughout study completion for each patient
Safety of administration of IL12-L19L19, assessed by Common Toxicity Criteria (version 5.0, CTCAE)
次要结局
- AUC of IL12-L19L19(In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion)
- T1/2 of IL12-L19L19(in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion)
- Plasma concentration of IL12-L19L19(30 min prior injection in week from 1 to 8, at End-of-Treatment Visit and Follow Up 1; in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2h, 4h and 24h after end of infusion)
- Cmax of IL12-L19L19(in week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion)
- Tmax of IL12-L19L19(In week 1 and 3: 15 min after start of infusion, 60 min after start of infusion, end of infusion, 2 h after end of infusion, 4 h after end of infusion, 24 h after end of infusion)
- HAFA(At week 1, 2, 3 and 4)
- For Part II: ORR(At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.)
- For Part II: DoR(At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.)
- For Part II: PFS(At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.)
- For Part II: OS(At 8 weeks, 16 weeks, 24 weeks, 36 weeks and 48 weeks.)
研究者
研究点 (12)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase I/II Study of MK-3475 in Combination with Trametinib and Dabrafenibadvanced or metastatic melanoma - all parts of the trialadvanced (unresectable and/or metastatic) solid tumours - Parts 4 and 5MedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864MedDRA version: 21.1Level: LLTClassification code 10053571Term: MelanomaSystem Organ Class: 100000004864EUCTR2015-000681-55-DKMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.190
进行中（未招募）
1 期
Phase I/II Study of MK-3475 in Combination with Trametinib and DabrafenibEUCTR2015-000681-55-ITMERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC.219
进行中（未招募）
1 期
A study to investigate the use of pazopanib and MK-3475 together to treat kidney cancer.MedDRA version: 20.1Level: PTClassification code 10073251Term: Clear cell renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Renal Cell CarcinomaEUCTR2013-003785-14-GBovartis Pharma Services AG42
招募中
1 期
BC008-1A Injection for Recurrent CNS WHO G4 GliomaGlioma Tumor RecurrenceGlioma, Recurrent High GradeGlioblastomas (GBM)Glioblastoma WHO Grade IVGliomaNCT06773481Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.40
招募中
不适用
A phase I study assessing the safety and performance of VB5-845D-800CW, an fluorescent agent, for the intraoperative detection of gastrointestinal cancerNL-OMON27469eiden University Medical Center (LUMC)34